Caplin Point Laboratories’ wholly owned subsidiary -- Caplin Steriles has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the recently concluded inspection in June 2019.
USFDA has completed inspection at Caplin Steriles’ Injectable site at Gummidipoondi between June 6 and June 14, 2019. This was the third successful USFDA audit at the plant since 2016.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
